Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape

Hepatocellular carcinoma (HCC) develops through cooperation between altered hepatocytes, chronic liver injury and a stromal and immune microenvironment. Genomic alterations and signaling abnormalities provide a rationale for treatment development, but pathway activation rarely identifies therapeutic dependence alone. This narrative review connects hepatic stellate cell states, tumor cell plasticity, genomic instability and four selected signaling pathways with antigen presentation, immune exclusion and clinical treatment evidence. Targeted searches were updated through 6 October 2026, retaining foundational work and prioritizing recent studies. Single-cell and spatial analyses reveal that stellate cells and cancer-associated fibroblasts can exert opposing effects according to their state and location. Similarly, CTNNB1-associated signaling can favor immune exclusion, but mutation status does not fully capture immune context or establish universal resistance to checkpoint combinations. Intratumoral dendritic cell and lymphocyte organization, suppressive myeloid niches and humoral responses provide complementary explanations of treatment heterogeneity. Randomized trials support selected antiangiogenic and checkpoint combinations in unresectable HCC, while negative trials and updated adjuvant results demonstrate the limits of extrapolating biological rationale across regimens and disease stages. The synthesis distinguishes experimental causality, patient-level association and clinically validated benefit. Translation requires compartment-specific target assessment, representative sampling and prospective biomarker evaluation within a defined treatment setting, alongside assessment of liver reserve.

Authors

Publication Details

Journal
Medical Sciences
Published
2026-11-16
DOI
https://doi.org/10.3390/medsci14070789
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape

Raluca Mitea, Alexandru Burlacu, A Vâţă, Mariana Floria et al.
1 links
Medical Sciences
Hepatocellular Carcinoma Treatment and Prognosis
article

Hepatocellular Carcinogenesis: Signaling, Stromal Heterogeneity and Immune Escape

Raluca Mitea, Alexandru Burlacu, A Vâţă, Mariana Floria, Alexandra Rotaru, Mathilde Leonard, Gina Botnariu, Elena Cojocaru, Daniela Maria Tanase, Alexandru-Florinel Oancea, Ionela-Larisa Miftode, Gabriela Crăciun
article en

Abstract

Hepatocellular carcinoma (HCC) develops through cooperation between altered hepatocytes, chronic liver injury and a stromal and immune microenvironment. Genomic alterations and signaling abnormalities provide a rationale for treatment development, but pathway activation rarely identifies therapeutic dependence alone. This narrative review connects hepatic stellate cell states, tumor cell plasticity, genomic instability and four selected signaling pathways with antigen presentation, immune exclusion and clinical treatment evidence. Targeted searches were updated through 6 October 2026, retaining foundational work and prioritizing recent studies. Single-cell and spatial analyses reveal that stellate cells and cancer-associated fibroblasts can exert opposing effects according to their state and location. Similarly, CTNNB1-associated signaling can favor immune exclusion, but mutation status does not fully capture immune context or establish universal resistance to checkpoint combinations. Intratumoral dendritic cell and lymphocyte organization, suppressive myeloid niches and humoral responses provide complementary explanations of treatment heterogeneity. Randomized trials support selected antiangiogenic and checkpoint combinations in unresectable HCC, while negative trials and updated adjuvant results demonstrate the limits of extrapolating biological rationale across regimens and disease stages. The synthesis distinguishes experimental causality, patient-level association and clinically validated benefit. Translation requires compartment-specific target assessment, representative sampling and prospective biomarker evaluation within a defined treatment setting, alongside assessment of liver reserve.

Medical SciencesVol. 14(7)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon